



NDA 205489

**NOTIFICATION OF  
NON-COMPLIANCE WITH PREA**

Neos Therapeutics Brands, LLC  
Attention: Lilly Vasquez  
Regulatory Affairs Manager  
2940 N. Highway 360, Suite 400  
Grand Prairie, TX 75050

Dear Lilly Vasquez:

Please refer to your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, which was approved on June 19, 2017.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 3222-4, which was deferred until August 31, 2023.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a “**DEFERRAL EXTENSION REQUESTED**” in your response. We note that you requested a deferral extension on March 8, 2021; however, we determined that your request did not qualify for an extension.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a “**RESPONSE TO PREA NON-COMPLIANCE LETTER.**” To facilitate our review, submit this information to your NDA with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, please contact Ann Sohn, PharmD, Regulatory Project Manager, at 301-796-2232 or [ann.sohn@fda.hhs.gov](mailto:ann.sohn@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Tiffany R. Farchione, MD  
Director  
Division of Psychiatry  
Office of Neuroscience  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TIFFANY R FARCHIONE  
03/27/2024 01:32:05 PM